ConCallIQ
Go Pro
DRREDDY Diversified 24 Jul 2024

Dr. Reddy's Laboratories Limited — Q1 FY25

Dr.

bullish high
Compare with...
Revenue ₹7,673 Cr +14%
EBITDA ₹2,160 Cr +1%
EBITDA Margin 28.2% -357bps
Duration
Read Time 1 min read

✓ Verified against BSE filing

Risk Intelligence

Material risks this quarter

Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.

Risks

R

US price erosion in generics

Pricing pressure in some key products partially offset volume gains in North America.

medium · management_commentary
R

Freight cost impact from Middle East conflict

Increased freight rates due to Red Sea route issues and air shipments added tens of crores to costs.

medium · management_commentary
R

SG&A step-up sustainability

SG&A jumped 28% YoY; analyst questioned if one-offs were included. Management attributed to investments and freight, but full-year guidance implies normalization.

medium · analyst_question
R

Cash flow moderation from factoring changes

Free cash flow was lower due to reduced factoring in the US; management expects normalization but it introduces volatility.

low · analyst_question